Valera Health: The company raised $44.5 million of venture funding from undisclosed investors on October 7, 2022. The company is a developer of behavioral healthcare software designed to offer personalized mental health services.
Alloy Therapeutics: The company raised $41.7 million through a combination of debt and Series D venture funding in a deal led by 8VC and Mubadala Capital-Ventures on October 3, 2022, putting the company’s pre-money valuation at $750 million. The company is a developer of a drug discovery platform designed to promote and facilitate antibody discovery projects.
InStride Health: The company raised $26 million of venture funding from .406 Ventures, Valtruis and Mass General Brigham Ventures on October 3, 2022. The company is a provider of anxiety and OCD treatment intended to offer enhanced mental health to children, teens, and young adults.
Gate Neurosciences: The company raised $25 million of venture funding from Innoviva, Luson BioVentures and BioCrossroads on October 5, 2022. The company is a developer of next-generation therapeutics designed to treat neurologic and psychiatric disorders.
Araris Biotech: The company raised $24 million of venture funding in a deal led by Pureos Bioventures and 4BIO Capital on October 4, 2022. The company is a developer of an antibody-drug conjugate linker technology designed to deliver potent drugs very specifically to the targeted tissue.
Vergent Bioscience: The company raised $21.5 million of Series B venture funding in a deal led by Orlando Health on October 4, 2022. The company is a developer of molecular imaging probes designed for diagnosis and removal of cancer cells.
Switch Therapeutics: The company raised $19.9 million of venture funding from undisclosed investors on October 4, 2022. The company is an operator of a next generation RNAi therapeutics business based in San Francisco, California.
Genetesis: The company raised $17.5 million of venture funding in a deal led by Mithril Capital Management on October 6, 2022. The company is a developer of a biomagnetic imaging tool designed to improve patients’ health and outcomes of life.
Sensorium Therapeutics: The company raised $15.5 million of venture funding from undisclosed investors on October 4, 2022. The company is an operator of drug discovery platform intended to develop novel FDA-approved psychoactive medicines.
Acurable: The company raised EUR 11 million of Series A venture funding in a deal led by Kibo Venture Partners on October 3, 2022. The company is a developer of a wearable device designed to automatically and accurately measure breathing and cardiac vital signs.
Posos: The company raised EUR 9.8 million of venture funding from Sofiouest, Captech Santé and Nord France Amorçage on October 7, 2022. The company is a developer of medical information software designed for prescription management.
Starlight Cardiovascular: The company closed on $9.5 million of an $11.5 million planned round of Series A venture funding in a deal led by Bird B on October 4, 2022. The company is a developer of a medical device intended to treat babies born with congenital heart disease.
Cardio Diagnostics: The company raised $6.5 million of venture funding from undisclosed investors on October 4, 2022. The company is a developer of medical kits designed for early detection and prevention of heart disease.
ClostraBio: The company raised $4 million of Series A1 venture funding in a deal led by Portal Innovations on October 7, 2022. The company is a developer of biopharmaceuticals intended to offer therapeutics for food allergies.
RadioMedix: The company is in the process of raising Series A venture funding from Portland Investment Counsel and other undisclosed investors on October 7, 2022. The company is an operator of a biotechnology firm intended to focus on targeted radio-pharmaceuticals for diagnosis, monitoring, and therapy of cancer.
